Hindustan Unilever informed that the National Company Law Tribunal (NCLT) Chandigarh has approved a scheme of amalgamation between GlaxoSmithKline Consumer Healthcare and the company.
The FMCG major had announced on 6 November 2019 that the scheme of amalgamation was previously approved by the National Company Law Tribunal, Mumbai Bench vide it's order dated 24 September 2019.It added that the effective date of the scheme will be communicated upon being finalized by the Transferor Company (GlaxoSmithKline Consumer Healthcare) and the Company (HUL), in accordance with the procedure specified under the Scheme approved by the Mumbai NCL T and Chandigarh NCLT.
Shares of Hindustan Unilever added 0.21% to Rs 2245.60 while those of Glaxosmithkline Consumer Healthcare gained 1.11% to Rs 9745.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app